Open AccessImpact of ELISA and immunoblot as diagnostic tools one year after eradication of Helicobacter pylori in a multicentre treatment study
Author(s) -
Kist Manfred,
Strobel Sonja,
Kirchner Thomas,
Dammann HansGerd
Publication year - 1999
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1111/j.1574-695x.1999.tb01289.x
Subject(s) - helicobacter pylori , antibody , serology , caga , immunology , antigen , immunoglobulin g , immunoglobulin a , spirillaceae , biology , medicine , gastritis , biochemistry , virulence , gene
The performance of serological tests for Helicobacter pylori infections is hampered by the persistence of antibodies after eradication therapy or spontaneous healing. Detection of different antigens or immunoglobulin classes might have an impact on the validity of serodiagnosis. The aim of this study was to assess the decrease in IgA and IgG antibody levels after eradication of H. pylori. Serum samples of 242 patients with active duodenal ulcer were tested with the ELISA and the immunoblot (IB) techniques for H. pylori ‐specific IgA and IgG antibodies before therapy and 1 year after successful eradication. From a total of 81 patients paired sera were available. At the end of the follow‐up period ELISA antibody titres from the IgA class had decreased from a mean value of 6.69 to 4.26 units ( P =0.0001 ), and IgG class antibody titres from a mean value of 21.9 to 12.1 units ( P =0.0001 ). Regarding seroreversion, from 34 initially IgA positive sera 16 (47%), and from 74 IgG positive sera 18 (24%), had definitively reverted to ‘negative’. One year after eradication, when tested with the immunoblot, the antibody responses against specific antigens of 37% IgA‐positive sera (23/62) and 8% IgG‐positive sera (6/78) reverted to ‘negative’, compared to a seroreversion rate of 27% of the anti‐CagA IgA‐positive sera (18/67) and of 9% of the anti‐CagA IgG‐positive sera (7/79). In conclusion, despite an overall significant decrease of H. pylori antibodies, both tests cannot be recommended for monitoring treatment success.